p95HER2 and breast cancer

Joaquín Arribas, José Baselga, Kim Pedersen, Josep Lluís Parra-Palau

Research output: Contribution to journalReview articleResearchpeer-review

135 Citations (Scopus)

Abstract

A subtype of HER2-positive tumors with distinct biological and clinical features expresses a series of carboxyterminal fragments collectively known as p95HER2. One of these fragments, named 100- to 115-kDa p95HER2 or 611-CTF, is hyperactive because of its ability to form homodimers maintained by intermolecular disulfide bonds. Despite lacking the majority of the extracellular domain, this HER2 fragment drives breast cancer progression in vivo. The recent availability of specific anti-p95 antibodies has confirmed previous results indicating that the expression of p95HER2 is predictive of poor prognosis and correlates with resistance to the treatment with trastuzumab, a therapeutic antibody directed against the extracellular domain of HER2. ©2011 AACR.
Original languageEnglish
Pages (from-to)1515-1519
JournalCancer Research
Volume71
Issue number5
DOIs
Publication statusPublished - 1 Mar 2011

Fingerprint Dive into the research topics of 'p95HER2 and breast cancer'. Together they form a unique fingerprint.

Cite this